Evaluation of the Long-Term Tolerability and Clinical Benefit of Vorinostat in Patients With Advanced Cutaneous T-Cell Lymphoma
Madeleine Duvic(Cancer Clinic), Larisa J. Geskin(Columbia University Irving Medical Center), A S Gunchenko(Merck (Japan)), Kathleen Boileau(Merck (Japan)), Eric C. Vonderheid(Ashford and St Peter's Hospitals NHS Foundation Trust), Syed Rizvi(Merck (Japan)), Justin L. Ricker(Merck (Japan)), Rachel Abuav(Johns Hopkins University), Elise A. Olsen(Durham Technical Community College), Theresa Pacheco(University of Colorado Anschutz Medical Campus), Cong Chen(Fujian University of Traditional Chinese Medicine), Sareeta Parker(Ashford and St Peter's Hospitals NHS Foundation Trust), Debra Breneman(University of Cincinnati), César Sanz-Rodrı́guez(Merck (Spain))
Cited by 97
Related Papers
Treatment of Cutaneous T-Cell Lymphoma by Extracorporeal Photochemotherapy
|New England Journal of Medicine|1987|1.2k
Clinical End Points and Response Criteria in Mycosis Fungoides and Sézary Syndrome: A Consensus Statement of the International Society for Cutaneous Lymphomas, the United States Cutaneous Lymphoma Consortium, and the Cutaneous Lymphoma Task Force of the European Organisation for Research and Treatment of Cancer
|Journal of Clinical Oncology|2011|657
Pivotal Phase III Trial of Two Dose Levels of Denileukin Diftitox for the Treatment of Cutaneous T-Cell Lymphoma
|Journal of Clinical Oncology|2001|610